Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986421 in Healthy Participants
NCT05517837Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in immune system diseases comparing BMS-986421 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events up to 8 Weeks, Number of participants with physical examination abnormalities up to 8 Weeks and 3 more. Started Sep 2022; status: terminated.
02
Drugs
BMS-986421
03
Conditions
immune system diseases
Beyond the preview
Go deeper on NCT05517837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517837.